

ZORYVE[®]

(roflumilast) cream 0.3%

If you have prescribed ZORYVE,

Get Patients Started

Consider including the following information in the prescription if clinically appropriate:

Possible ICD-10 Code ^{1*}	L40, L40.0, L40.8, L40.9
Has your patient tried and failed medications? ^{2**}	<ul style="list-style-type: none"> • Topical corticosteroids • Topical vitamin D analogs • Topical retinoids • Topical salicylic acid • Topical anthralin
List special treatment location(s), if any*	Facial, genital, or intertriginous areas
You may wish to include a note	ZORYVE may not be substituted

Let your patients know to:



Respond to a call from the pharmacy



Sign up for the ZORYVE Direct Savings Card Program, if they are an eligible commercially insured patient[†]

To enroll, patients can scan the QR Code to text **SAVE** to **440-4ZORYVE** (440-4967983)



^{*}Always add relevant clinical information for your specific patient based on your own professional judgment.
[†]Subject to eligibility criteria and maximum benefit limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Terms and Conditions may be viewed online at www.zoryvedirect.com/terms.



Learn more about the ZORYVE Direct Savings Card Program for commercially insured patients at www.zoryvedirect.com

INDICATION

ZORYVE® (roflumilast) is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

The most common adverse reactions ($\geq 1\%$) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).

Please see accompanying full Prescribing Information for ZORYVE.

References: 1. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHO Version for 2019-covid-expanded. <https://icd.who.int/browse10/2019/en#/L40>. Accessed October 26, 2022. 2. Menter et al. *J Am Acad Dermatol*. 2009;60(4):643-659.

© 2022 Arcutis Biotherapeutics, Inc. All rights reserved.

US-COM-151-00006 v1.0 11/2022

